Rosecliff Acquisition Corp I furnishes investor presentation for proposed Spectral MD business combination

Spectral AI, Inc.

DeepView System received FDA Breakthrough Device Designation for burn indication in 2018.
Spectral MD has secured over $130 million in U.S. government contracts for burn and DFU development.
Initial target markets (burn wounds + diabetic foot ulcers) estimated at ~$14.7 billion by 2028.
Proprietary AI database contains more than 263 billion clinically validated data points.
Regulatory submissions (FDA, CE, UKCA) expected to commence in 2023 based on positive study outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.